Eosinophils in asthma--closing the loop or opening the door?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

38 citing papers in PubMed.

1. Association between the systemic inflammation response index and mortality in the asthma population.Frontiers in medicine · 2024
   Article
2. Frontline Science: Eosinophil-deficient MBP-1 and EPX double-knockout mice link pulmonary remodeling and airway dysfunction with type 2 inflammation.Journal of leukocyte biology · 2017
   Article
3. Lung Pathologies in a Chronic Inflammation Mouse Model Are Independent of Eosinophil Degranulation.American journal of respiratory and critical care medicine · 2017
   Article
4. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.Therapeutic advances in respiratory disease · 2017
   Review
5. Biological Modulators in Eosinophilic Diseases.Clinical reviews in allergy & immunology · 2016
   Review
6. Novel Therapies for Eosinophilic Disorders.Immunology and allergy clinics of North America · 2015
   Review
7. Management of the patient with eosinophilic asthma: a new era begins.ERJ open research · 2015
   Review
8. Type 2 cytokines: mechanisms and therapeutic strategies.Nature reviews. Immunology · 2015
   Review
9. Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases.Journal of asthma and allergy · 2015
   Review
10. Trif-dependent induction of Th17 immunity by lung dendritic cells.Mucosal immunology · 2015
    Article
11. Re-defining the unique roles for eosinophils in allergic respiratory inflammation.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2014
    Review
12. Changing roles of eosinophils in health and disease.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2014
    Review
13. Mitochondria in the center of human eosinophil apoptosis and survival.International journal of molecular sciences · 2014
    Review
14. Tumour necrosis factor-α regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-κB and AP-1.PloS one · 2014
    Article
15. Proteolytic Activity Present in House-Dust-Mite Extracts Degrades ENA-78/CXCL5 and Reduces Neutrophil Migration.Journal of allergy · 2014
    Article
16. Expression profiling of differentiating eosinophils in bone marrow cultures predicts functional links between microRNAs and their target mRNAs.PloS one · 2014
    Article
17. Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.Current allergy and asthma reports · 2013
    Review
18. Aspirin-intolerant asthma: a comprehensive review of biomarkers and pathophysiology.Clinical reviews in allergy & immunology · 2013
    Review
19. Recurrent blood eosinophilia in ulcerative colitis is associated with severe disease and primary sclerosing cholangitis.Digestive diseases and sciences · 2013
    Article
20. Clinical utility of asthma biomarkers: from bench to bedside.Biologics : targets & therapy · 2013
    Review

Corrections and comments

• Commented on by
  Anti-interleukin-5 therapy and severe asthma.2009
• Comment on
  Mepolizumab and exacerbations of refractory eosinophilic asthma.2009
• Comment on
  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as